The Patent Finder

Darwin Molecular Corporation

Also on record
Records under this name other than patents Darwin Molecular Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Darwin Molecular Corporation

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,381,409Antibodies specific for sclerostin and methods of screening and use therefor
Formerly held
Term ended
Term ended Jul 1, 2025 · High confidence
Term endedTerm ended Jul 1, 2025High confidence
US 11,702,468Antibodies Specific for Sclerostin and Methods for Increasing Bone Mineralization
Formerly held
Term ended
Term ended Sep 18, 2024 · Medium confidence
Term endedTerm ended Sep 18, 2024Medium confidence
US 9,657,095Antibodies Specific for Sclerostin and Methods for Increasing Bone Mineralization
Formerly held
Term ended
Ended no later than Jun 16, 2024 · Medium confidence
Term endedEnded no later than Jun 16, 2024Medium confidence
US 7,868,134Immunogenic Peptides Derived from Sclerostin
Formerly held
Term ended
Ended no later than Jun 15, 2024 · Medium confidence
Term endedEnded no later than Jun 15, 2024Medium confidence
US 8,563,271Antibodies Specific for Sclerostin and Methods for Increasing Bone Mineralization
Formerly held
Term ended
Term ended Jun 15, 2024 · High confidence
Term endedTerm ended Jun 15, 2024High confidence
US 8,992,911Antibodies Specific for Sclerostin and Methods for Increasing Bone Mineralization
Formerly held
Term ended
Ended no later than Jun 15, 2024 · Low confidence
Term endedEnded no later than Jun 15, 2024Low confidence
US 9,011,856Antibodies Specific for Sclerostin and Methods for Increasing Bone Mineralization
Formerly held
Term ended
Ended no later than Jun 15, 2024 · Medium confidence
Term endedEnded no later than Jun 15, 2024Medium confidence
US 7,572,899Compositions and methods for increasing bone mineralization
Formerly held
Term ended
Term ended Dec 24, 2020 · USPTO record
Term endedTerm ended Dec 24, 2020USPTO record
US 7,578,999Antibodies Specific for Sclerostin
Formerly held
Term ended
Ended no later than Jul 4, 2020 · Low confidence
Term endedEnded no later than Jul 4, 2020Low confidence
US 7,192,583Methods for modulating bone mineralization
Formerly held
Term ended
Term ended Feb 6, 2020 · USPTO record
Term endedTerm ended Feb 6, 2020USPTO record
10 of 24 patents shown.
Pro members see all 24.
Pro members: see all 24 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited